A Phase Ib, Open-Label, Multicenter Study to Evaluate the Safety, Pharmacokinetics, and Activity of Belvarafenib as a Single Agent and in Combination With Either Cobimetinib or Cobimetinib Plus Nivolumab in Patients With NRAS-Mutant Advanced Melanoma Who Have Received Anti-PD-1/PD-L1 Therapy
Latest Information Update: 19 Aug 2024
At a glance
- Drugs Atezolizumab (Primary) ; Belvarafenib (Primary) ; Cobimetinib (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions
- Sponsors Genentech
- 15 Feb 2024 Status changed from recruiting to active, no longer recruiting.
- 01 Dec 2023 Planned End Date changed from 1 Sep 2024 to 28 Nov 2025.
- 01 Dec 2023 Planned primary completion date changed from 6 Nov 2023 to 28 Nov 2025.